Business
This section features DDW articles on the business side of pharma & drug discovery
Page 1 to 16 of 102 |     NEXT PAGE >
How Mergers and Acquisitions Will Drive Oncology Research in 2019 By Dr Michael Seiler Spring 2019
The year has got off to a fast start for oncology drug discovery, with numerous mergers, acquisitions and collaborations announced in quick succession.

Read More

Integrated Platform Drug Discovery and Development Companies - Part 2: comparative analysis By Dr Stephen Naylor and Dr Kirkwood A. Pritchard Jr Spring 2019
Large pharmaceutical companies have struggled to efficiently implement tools, technologies and platforms into their drug discovery and development (DDD) programmes.

Read More

Fostering Multidisciplinary Collaboration in Drug Discovery By Professor Zeynep Erden, et al. Spring 2019
Drug discovery teams combine specialists with in-depth knowledge from a variety of scientific disciplines. Such diversity in thought worlds poses a challenging exercise in cross-disciplinary collaboration and project coordination.

Read More

Good Laboratory Practice - To GLP or not to GLP? By Scott Hickman, Dr Brian Ogilvie and Tim Patterson Winter 2018/19
Good Laboratory Practices (GLP), are federal regulations that require implementation of a robust quality management system to ensure the validity, integrity and reliability of non-clinical safety data submitted for regulatory evaluation and approval.

Read More

Integrated Platform Drug Discovery and Development Companies - Part 1 By Dr Urban A. Kiernan and Dr Stephen Naylor Fall 2018
Technology was lauded as the saviour of the drug discovery and development (DDD) process during the late 1990s. A myriad of independent companies developed and offered ‘innovative’ tools, technologies and platforms (TTPs) to pharmaceutical companies in order to mitigate the time, cost and risk of developing new therapeutic drugs.

Read More

Astrazeneca R&D - Improving Drug Development Productivity With Better Predictivity By Dr Menelas Pangalos & Steve Rees et al. Summer 2018
Changing demands in global healthcare over the past 15 years have led to greater complexity and spiralling costs in drug development. The average price tag of taking a new drug from discovery to completion of Phase III clinical trials is now $2.87 billion (1), which means informed decisions need to be made early on about which compounds to pursue.

Read More

Disruptive Approaches To Accelerate Drug Discovery and Development (Part 1) By Ibis Sanchez- Serrano, Dr Tom Pfeifer and Dr Rathnam Chaguturu Spring 2018
This article is part 1 of 2, and covers tools, technologies and the core model of disruptive approaches to accelerate drug discovery and development.

Read More

Emerging Drug Discovery Alliance Models By Dr Swati Prasad, Mary Louise Bell & Dr Charles McOsker Winter 2017/18
The current environment for early-stage drug discovery and development is fluid and the probability of success continues to be challenging.

Read More

The Discoverome - Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Spring 2017
Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and fast.

Read More

Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Winter 16/17
Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved around 200 novel drugs for human use (1,2). Not a large number considering the Pharmaceutical Research and Manufacturers of America (PhRMA) citation that for every 5,000 to 10,000 compounds that enter the pipeline, only one receives approval (3)

Read More

Digital Pharma - How Digital Is Reshaping The Pharma Arena By Ulrica Sehlstedt, Nils Bohlin, Fredrik de Mare and Richard Beetz Spring 2016
The pharmaceutical industry in the 20th and early 21st century has been in constant change, driven by both incremental and breakthrough innovations.

Read More

The Benefits of Pre-Competitive Collaboration in the Pharmaceutical Industry By Richard Holland Fall 2015
Pre-competitive collaboration allows a group of competing companies to come together to develop a solution for a problem that they all share, and from which none of them would gain a competitive advantage.

Read More

Valuation In Pharma Portfolio Management By Dr Michel Azoulay Winter 2015/16
Throughout the course of my career, I have been involved in a wide range of portfolio decisions and continue to be involved in them today. Over the years, it has been observed that despite cultural differences, pharma teams face similar problems.

Read More

Overcoming the Disruption Dip in the Aftermath of Mergers & Acquisitions By Roger Humphrey Fall 2015
M&A deals are disrupting the life science industry – and that’s good, mostly. Yet, when a company reshapes its facilities footprint in the wake of a consolidation, cost efficiency can be undermined by the dreaded ‘disruption dip’ in productivity. Here’s how to keep your workplaces and laboratories on track.

Read More

Therapeutic Drug Repurposing, Repositioning and Rescue Part II: Business Review By Dr Stephen Naylor, David M. Kauppi and Judge M. Schonfeld Spring 2015
There is an emerging consensus that the impact of Drug Repurposing, Repositioning and Rescue (DRPx) on the pharmaceutical industry is real and sustainable.

Read More

Business
Page 1 to 16 of 102 |     NEXT PAGE >